Ventyx Biosciences/$VTYX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Ticker
$VTYX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
81
ISIN
US92332V1070
Website
VTYX Metrics
BasicAdvanced
$167M
-
-$1.75
0.73
-
Price and volume
Market cap
$167M
Beta
0.73
52-week high
$3.21
52-week low
$0.78
Average daily volume
2.2M
Financial strength
Current ratio
19.571
Quick ratio
18.501
Long term debt to equity
4.081
Total debt to equity
4.553
Profitability
EBITDA (TTM)
-136.483
Management effectiveness
Return on assets (TTM)
-29.20%
Return on equity (TTM)
-46.04%
Valuation
Price to book
0.72
Price to tangible book (TTM)
0.72
Price to free cash flow (TTM)
-1.519
Free cash flow yield (TTM)
-65.82%
Free cash flow per share (TTM)
-154.01%
Growth
Earnings per share change (TTM)
-45.82%
3-year earnings per share growth (CAGR)
-14.20%
What the Analysts think about VTYX
Analyst ratings (Buy, Hold, Sell) for Ventyx Biosciences stock.
VTYX Financial Performance
Revenues and expenses
VTYX Earnings Performance
Company profitability
VTYX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ventyx Biosciences stock?
Ventyx Biosciences (VTYX) has a market cap of $167M as of June 30, 2025.
What is the P/E ratio for Ventyx Biosciences stock?
The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of June 30, 2025.
Does Ventyx Biosciences stock pay dividends?
No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Ventyx Biosciences dividend payment date?
Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ventyx Biosciences?
Ventyx Biosciences (VTYX) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.